How should tenecteplase be administered in acute myocardial infarction?

How to Administer Tenecteplase in Acute Myocardial Infarction

Tenecteplase should be given as a single intravenous weight-based bolus over 5-10 seconds, with dosing ranging from 30 mg to 50 mg based on body weight, ideally within 12 hours of symptom onset when primary PCI cannot be achieved rapidly. 1

Weight-Based Dosing Protocol

Tenecteplase dosing is strictly weight-tiered to optimize the patency-to-bleeding relationship 1, 2:

• <60 kg: 30 mg IV bolus
• 60-69 kg: 35 mg IV bolus
• 70-79 kg: 40 mg IV bolus
• 80-89 kg: 45 mg IV bolus
• ≥90 kg: 50 mg IV bolus

The drug is administered as a single bolus over 5-10 seconds, which represents a major practical advantage over alteplase's 90-minute infusion 1, 2. This weight-adjusted dosing (approximately 0.5-0.6 mg/kg) was developed based on exploratory analyses showing superior efficacy and safety compared to fixed dosing across varying patient weights 2.

Timing Considerations

Optimal window: Within 12 hours of symptom onset, with greatest benefit in the first 12 hours, particularly in patients presenting early with large anterior infarctions and low bleeding risk 1.

Late presentation (>12 hours): Consider fibrinolytic therapy in symptomatic patients with large areas of myocardium at risk or hemodynamic instability when PCI is unavailable, though benefit beyond 12 hours is not well-established 1.

Tenecteplase demonstrated reduced mortality compared to alteplase specifically in patients treated more than 4 hours after symptom onset (7% vs 9.2%, p=0.018), suggesting particular value in delayed presentations 3.

Contraindications to Screen Before Administration

Absolute Contraindications 1:

• Any prior intracranial hemorrhage
• Known structural cerebrovascular lesion (AVM, aneurysm)
• Known malignant intracranial neoplasm
• Ischemic stroke within 3 months (except acute ischemic stroke within 4.5 hours)
• Suspected aortic dissection
• Active bleeding or bleeding diathesis
• Significant closed-head or facial trauma within 3 months
• Intracranial/intraspinal surgery within 2 months
• Severe uncontrolled hypertension: SBP >180 mmHg or DBP >110 mmHg unresponsive to therapy

Relative Contraindications 1:

• Significant hypertension on presentation (SBP >180 or DBP >110 mmHg)
• History of ischemic stroke >3 months ago
• Traumatic or prolonged CPR (>10 minutes)
• Major surgery within 3 weeks
• Recent internal bleeding (2-4 weeks)
• Pregnancy
• Active peptic ulcer
• Oral anticoagulant therapy

Adjunctive Therapy

Tenecteplase must be combined with 1, 4:

• Aspirin (standard dosing)
• Anticoagulation: Either unfractionated heparin (weight-adjusted for 48 hours) or enoxaparin (for up to 7 days). The ASSENT-3 trial demonstrated that tenecteplase plus enoxaparin significantly reduced ischemic complications compared to unfractionated heparin (11.4% vs 15.4%, p=0.0002) 4.

Critical Post-Administration Management

Immediate transfer to PCI-capable center is mandatory after fibrinolytic administration 1. The pharmacokinetic profile shows tenecteplase has a biphasic disposition with initial half-life of 17-24 minutes and terminal half-life of 65-132 minutes, maintaining higher plasma concentrations than alteplase throughout 5.

Timing of Angiography 1:

• Failed reperfusion: Immediate angiography with rescue PCI
• Successful reperfusion: Early angiography between 2-24 hours with intent to perform PCI

Critical Pitfall: Do NOT Use Before Primary PCI

Warning: The ASSENT-4 PCI trial was terminated early due to worse outcomes when tenecteplase was administered before planned primary PCI with anticipated 1-3 hour delays 2. The composite endpoint of death/cardiogenic shock/CHF was significantly higher with tenecteplase plus PCI versus PCI alone (18.6% vs 13.4%, p=0.0045) 2. Tenecteplase should only be used when timely primary PCI cannot be achieved, not as facilitated PCI.

Reconstitution and Storage

Tenecteplase is supplied as lyophilized powder requiring reconstitution with 10 mL Sterile Water for Injection 2. Store at room temperature up to 30°C or refrigerated at 2-8°C 2. Do not use beyond expiration date 2.

Safety Profile

Tenecteplase demonstrated equivalent 30-day mortality to alteplase (approximately 6.2%) but with significantly reduced noncerebral bleeding (26.43% vs 28.95%, p=0.0003) 1, 3. Intracranial hemorrhage rates are similar between agents (0.93% for tenecteplase vs 0.94% for alteplase) 3. The improved bleeding profile is attributed to tenecteplase's 15-fold higher fibrin specificity and 80-fold reduced PAI-1 binding 5.